JAK2-negative acute monocytic leukemia with TET2 mutation in essential thrombocythemia with JAK2 mutation with literature review
暂无分享,去创建一个
H. Sakura | K. Kawauchi | K. Shimoda | T. Ogasawara | N. Mori | K. Shide | T. Ono | Shoko Marshall
[1] A. Rao,et al. Dysregulation of the TET family of epigenetic regulators in hematopoietic malignancies. , 2019, Blood.
[2] B. Stein,et al. Therapy-associated leukemic transformation in myeloproliferative neoplasms - What do we know? , 2019, Best practice & research. Clinical haematology.
[3] L. Holmberg,et al. Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study. , 2018, Leukemia research.
[4] K. Mills,et al. Epigenetics in Myeloproliferative Neoplasms , 2017, Journal of cellular and molecular medicine.
[5] W. Vainchenker,et al. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. , 2017, Blood.
[6] A. Tefferi,et al. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors , 2015, Blood Cancer Journal.
[7] Christian Beisel,et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. , 2014, Blood.
[8] A. Iwama,et al. TET2 is essential for survival and hematopoietic stem cell homeostasis , 2012, Leukemia.
[9] E. Pronier,et al. Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. , 2011, Blood.
[10] F. Granath,et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] B. Quesnel,et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). , 2010, Blood.
[12] R. Kusec,et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. , 2010, Blood.
[13] H. Hsiao,et al. Disappearance of JAK2 V617F mutation in a rapid leukemic transformed essential thrombocythemia patient. , 2008, Leukemia research.
[14] C. Lam,et al. Reemergence of JAK2 V617F clone heralds extramedullary leukemia relapse after BMT for transformed essential thrombocytosis , 2006, Annals of Hematology.
[15] Soon-Siong Teo,et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. , 2006, Blood.
[16] P. Campbell,et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. , 2006, Blood.
[17] R. Liang,et al. Transformed essential thrombocytosis with a JAK2 V617F mutation relapsing as JAK2 mutation-negative leukaemia after allogeneic stem cell transplantation , 2006, Bone Marrow Transplantation.
[18] E. Estey,et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. , 2005, Blood.